Poland to Increase Tobacco Consumption Tax by 2025, E-cigarettes up 75%

Regulations by 2FIRSTS.ai
Jul.10.2024
Poland to Increase Tobacco Consumption Tax by 2025, E-cigarettes up 75%
Poland plans to gradually increase tobacco consumption taxes by 2025, with cigarettes seeing a 25% hike and e-cigarettes 75%.

According to the July 10th report from "Fakt", the Polish Ministry of Finance and Ministry of Health have been indicating that tobacco product consumption taxes will soon be adjusted. The plan is to gradually increase the tax rates, with the expectation that by 2025, consumption taxes on tobacco products will reach new highs: a 25% increase for cigarettes, a 38% increase for hand-rolled cigarettes, a 50% increase for innovative tobacco products, and a 75% increase for e-cigarettes. This major change has caused shockwaves within the industry.


In the next three years, the consumption tax on all tobacco products in Poland is set to increase, with a potential 60% rise for cigarettes, up to 90% for hand-rolled cigarettes, 85% for innovative tobacco products, and 150% for e-cigarettes. It is estimated that by 2025, these tax adjustments will raise the price of the cheapest pack of cigarettes to 20 zlotys (approximately $5.09 USD), while e-cigarettes are expected to see significant tax hikes of 75%, 50%, and 25% between 2025 and 2027.


The Chief Economist of the Polish Federation of Entrepreneurs, Łukasz Kozłowski, also expressed his concerns about the Ministry of Finance on X Service (formerly Twitter). He pointed out that the government's actions violate article 11 of the coalition agreement, which stipulates that tax changes must be notified at least six months in advance, but now the government is notifying them of the need to face additional consumption tax increases in a shorter period of time.


The Ministry of Finance believes that Polish people will not stop smoking, but will instead shift their focus to the grey market and smuggled products.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11
Puerto Rico House Files P.C. 1070 to Ban Flavored Vaping Product Sales to Under-21s
Puerto Rico House Files P.C. 1070 to Ban Flavored Vaping Product Sales to Under-21s
According to a statement from the Puerto Rico House of Representatives, House Speaker Carlos Méndez and Rep. Pedro Julio Santiago announced the filing of House Bill 1070 (P.C. 1070), which would prohibit sales to people under 21 of vaping devices, liquids, or cartridges featuring a flavor and/or aroma other than nicotine.
Jan.29 by 2FIRSTS.ai
Thai Health Authorities: Nicotine Pouches Classified as Tobacco; Sales Must Comply with 2017 Act
Thai Health Authorities: Nicotine Pouches Classified as Tobacco; Sales Must Comply with 2017 Act
Thailand’s Disease Control Department has warned that nicotine pouches (“Snus”) are classified as tobacco products and must comply with the Tobacco Products Control Act B.E. 2560 (2017). Officials said they have received complaints about sales and promotional activities, and stressed that these products must not be displayed or promoted at points of sale.
Feb.02 by 2FIRSTS.ai
Kenya’s BAT Kenya resumes Velo nicotine pouches after citing regulatory clarity
Kenya’s BAT Kenya resumes Velo nicotine pouches after citing regulatory clarity
BAT Kenya says it has resumed sales of Velo oral nicotine pouches after receiving regulatory clarity, reinforcing its push into non-combustible products as cigarette consumption falls.The company reported a 10% drop in turnover in 2025, with revenue closing at KSh23.2 billion (about $178.64 million), largely attributed to the growing presence of illegal tobacco products.
Mar.03 by 2FIRSTS.ai
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.
Feb.11
BAT FY2025 Results Review Series by 2Firsts
BAT FY2025 Results Review Series by 2Firsts
Feb.12